Rezdiffra Prescribing Information (March 2024 FDA Label)
FDA approved resmetirom March 14, 2024 for MASH with F2-F3 fibrosis. Dosing is 80mg or 100mg daily; not legally compoundable since no shortage or generic exists.
Resmetirom: Regulatory History
1 source-based articles maintained by the HealthRX.com Editorial Team.
1articles
1topic areas covered
May 26, 2026latest review
Resmetirom: Regulatory History library
Showing 1 of 1 clinical reviews.